Authors

Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

COVID-19’s Effect on the Brain

As many as 1 in 3 infected with COVID-19 have longer-term neurological or mental health symptoms.

Emerging Multiple Sclerosis Treatments

From Standard-of-Care Injectables to Next-Generation S1P Receptor Modulators, Newer Treatments Offer Patients Options

The State of Biomarkers in Multiple Sclerosis

As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.

Patient Evaluation for Excessive Daytime Sleepiness

Excessive daytime sleepiness is a hallmark of a number of sleep disorders, and ensuring the proper diagnosis and management of those presenting with it is crucial to care.

Sex Dependent Decreases in REM Sleep After TBI and the Impact it May Have on Recovery

Grace Griesbach, PhD, the national director of clinical research for Centre for Neuro Skills, discussed the impact of REM sleep on memory following traumatic brain injury and the importance of considering sex as a biological variable.

Harnessing Genetic Knowledge for Targeted Therapies in Child Neurology: Olivia Kim-McManus, MD

At CNS 2025, the child neurologist at Rady Children's Hospital-San Diego talked about the expanding role of genetics for diagnosis and treatment in pediatric neurology. [WATCH TIME: 5 minutes]

The Evolutionary Arch of Stereoelectroencephalography in the United States

SEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.

Overviewing Phase 1/2 PACIFIC Trial of Bexicaserin in Developmental Epileptic Encephalopathies: Ingrid Scheffer, AO, PhD, FRACP, FAHMS, FAA

The laureate professor at the University of Melbourne detailed the design and promising results of the PACIFIC trial of bexicaserin, an agent in development for epileptic encephalopathies. [WATCH TIME: 4 minutes]

Navigating Treatment Decision-Making in Multiple Sclerosis

In a paradigm with many options, once multiple sclerosis is confirmed as a patient’s diagnosis, physicians are left with 1 question: What do we choose for long-term treatment?

Advanced Imaging for Extended Stroke Treatment

With many patients presenting with an unknown time of last known well, establishing a tissue window using advanced imaging techniques may allow for more effective intervention and better outcomes.

Preventing Secondary Stroke: Practical Application of Updated Guidelines

Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.

Promising Disease-Modifying Therapies in Parkinson Disease

Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.

Translating Oculopharyngeal Muscular Dystrophy Research Into Clinical Application: Matthew Wicklund, MD

The professor of neurology at the University of Texas Health Science Center San Antonio discussed some of the challenges with therapeutic development for OPMD, as well as advances and barriers to gene therapy approaches. [WATCH TIME: 4 minutes]

Stroke Intervention: A New Application of Interventional Neuroradiology

New training pathways are needed to close the gap between capable-physician supply and the growing demand for thrombectomy.

Importance of Telehealth Services for the MS Population

Bryant Robinson, senior manager of government relations at the National MS Society, discussed how telehealth access has become vital for patients with multiple sclerosis who often lack nearby specialist care.

Key Sessions and Real-World Case Learning at PNS 2025: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc

A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting shared key sessions and trends clinicians should follow at the upcoming meeting, emphasizing collaboration, trial data, and clinical relevance. [WATCH TIME: 3 minutes]

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]

NeurologyLive® Clinician of the Month Spotlight: Stephanie C. Randle, MD, MS

As part of our monthly clinician spotlight, NeurologyLive® highlighted epilepsy expert Stephanie C. Randle, MD, MS, director of the Tuberous Sclerosis Complex Clinic at Seattle Children's Hospital.

Maximizing "On" Time: Longer-Lasting Levodopa Therapy Options for Parkinson's Disease

Preparing for the AI-Driven Future of Neurology: Elisabeth Marsh, MD

The associate professor of neurology at Johns Hopkins Medicine previewed a 2025 AUPN panel exploring AI’s clinical, research, and educational applications, along with the ethical considerations shaping its responsible adoption. [WATCH TIME: 2 minutes]

Let’s Get Moving: A Multidisciplinary Approach to Gait Rehabilitation in Multiple Sclerosis

Current research pushes to advance therapeutic possibilities and understand underlying neural mechanisms for gait impairments in individuals with the disease.

Muscular Dystrophy Association: A Hybrid Conference Featuring the Latest Advances in Neuromuscular Research, Therapy, and Clinical Care

The Muscular Dystrophy Association's annual meeting will take place in-person and virtually in Nashville, Tennessee, on March 13-16, with more than 950 in-person attendees and 130 presenters.

Therapeutics Aim at Modifying Alzheimer Disease

Disease-modifying agents will require early detection, including comprehensive evaluation of disease severity and alternative or confounding diagnoses. When the long-awaited moment arrives, when disease-modifying therapies finally are available for ADRDs…will we be ready?

A Team Approach to Asleep Deep Brain Stimulation

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

Comparable Evidence of Telehealth Benefits vs In-Person Care for Pediatrics: Gogi Kumar, MD

The division chief of child neurology at Dayton Children’s Hospital discussed findings from a study comparing patient satisfaction scores between telehealth and in-person visits in pediatric epilepsy care. [WATCH TIME: 4 minutes]

Durability and Next Steps in Advancing ARCUS Gene Editing Platform in DMD: Cassandra Gorsuch, PhD

The chief scientific officer at Precision Biosciences provided clinical insights on the durable potential of ARCUS gene editing and the company’s next steps toward in-human trials for Duchenne muscular dystrophy. [WATCH TIME: 4 minutes]